BioGaia AB Class B (DE:BGLA)
FRANKFURT:BGLA
BGLA Stock Chart & Stats
€9.63
-€0.19(-1.91%)
At close: 4:00 PM EST
€9.63
-€0.19(-1.91%)
Day’s Range― - ―
52-Week Range€8.38 - €12.32
Previous CloseN/A
Volume0.00
Average Volume (3M)28.00
Market Cap
€1.15B
Enterprise Value€11.96B
Total Cash (Recent Filing)€871.78M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)37.9
Beta0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding98,497,170
10 Day Avg. Volume36
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and a conservative balance sheet provide durable financial flexibility. Over a multi-month to multi-year horizon this lowers refinancing and interest-rate risk, supports investment in clinical studies, marketing or M&A, and preserves capacity for distributions during downturns.
Accelerating Revenue GrowthA marked acceleration in top-line growth signals durable commercial momentum across geographies and channels. Sustained higher growth supports scale economics, strengthens partner negotiating leverage, and increases the likelihood that R&D and brand investments will pay off over the next several quarters.
High Margins And Cash ConversionVery high gross and healthy net margins combined with near-par FCF conversion indicate durable pricing power and earnings quality. Strong cash conversion funds reinvestment, dividends or buybacks and reduces reliance on external funding, reinforcing long-term business resilience.
Bears Say
Margin CompressionA multi-year decline in margins points to structural pressures such as adverse mix, higher SG&A or production costs. If persistent, this reduces free cash flow per unit of revenue and limits the company's ability to fund growth or maintain return-on-capital targets despite rising sales.
Declining Equity And Asset LevelsEroding equity and asset bases can reduce the firm's capital cushion against shocks and limit capacity for capital-intensive initiatives. If declines are driven by distributions rather than reinvestment, the company may face constraints funding growth or absorbing adverse demand swings.
Inconsistent Cash Coverage Of EarningsVolatility in cash-to-earnings coverage signals working-capital or timing pressure that can impair free cash flow reliability. Over a medium-term horizon, inconsistent FCF weakens ability to sustain distributions, invest in growth initiatives, or absorb margin pressure without tapping reserves.
BioGaia AB News
BGLA FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest stock price was €8.38 and its highest was €12.32 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is €1.15B.
When is BioGaia AB Class B’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioGaia AB Class B’s earnings last quarter?
Currently, no data Available
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B does not currently pay dividends.
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in DE:BGLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
Technical Analysis
Options Prices
Currently, No data available
---